Free tool
FAERS Monitor: Rasonque
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220910 or its brand name (Rasonque, Daraxonrasib). Reports on generic versions are filed under their own applications.
Reports
10
Serious
10
100% of reports
Hospitalization
6
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dehydration4
- diarrhoea4
- nausea4
- vomiting4
- rash2
- stomatitis2
- abdominal pain upper1
- ageusia1
- blood potassium abnormal1
- blood pressure decreased1
- cardiac disorder1
- disease progression1
- dysgeusia1
- dyspnoea1
- fatigue1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood potassium abnormal | 1 | 789.4 | 122.9 | 196 |
| ageusia | 1 | 84.3 | 13.1 | 20 |
| stomatitis | 2 | 69.4 | 20.1 | 75 |
| dehydrationSignal | 4 | 63.1 | 29.5 | 187 |
| blood pressure decreased | 1 | 31.7 | 4.9 | 7 |
| dysgeusia | 1 | 28.3 | 4.4 | 6 |
| cardiac disorder | 1 | 22.5 | 3.5 | 5 |
| vomitingSignal | 4 | 17.9 | 8.4 | 49 |
| disease progression | 1 | 17.8 | 2.8 | 4 |
| diarrhoeaSignal | 4 | 13.0 | 6.1 | 34 |
| nauseaSignal | 4 | 10.6 | 5.0 | 27 |
| abdominal pain upper | 1 | 10.2 | 1.6 | 2 |
| rash | 2 | 9.7 | 2.8 | 8 |
| dyspnoea | 1 | 3.7 | 0.6 | 0 |
| fatigue | 1 | 2.7 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.